Biotechnology

Cogent Biosciences

Cogent Biosciences released FY2026 Q1 earnings on May 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5999 (forecast USD -0.5409)

Cogent Biosciences Inc Reports Q1 Loss, Preparing for New Drug Launch

Cogent Biosciences Achieves Expected Goals in Late-Stage GIST Treatment Trial

Cogent Biosciences to Present Preclinical Updates on Oncology Programs at AACR Annual Meeting

Cogent Biosciences' GIST drug application submission leads to 6% stock price drop

Fairmount Funds Management Reduces Holdings in Cogent Biosciences

Analysts Reiterate Buy Rating on Cogent Biosciences

Cogent Biosciences stock price rises, analysts raise target price

Cogent Biosciences' New Drug Application Accepted by FDA

Cogent Biosciences Announces Move to Pre-commercial Phase, Preparing for FDA Application

JPMorgan Analyst Reiterates Buy Rating on Cogent Biosciences

Cogent Biosciences released FY2025 annual earnings on February 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.5504 (forecast USD -2.2605)

Cogent Biosciences released FY2025 Q4 earnings on February 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7325 (forecast USD -0.5167)

Cogent Biosciences to Present Bezuclastinib Phase 2 Study Results in Adults with Non-progressing Systemic Mastocytosis

Cogent Biosciences Inc. Submits NDA to FDA

Analyst Sam Slutsky Maintains Buy Rating and Raises Price Target for Cogent Biosciences

Cogent Biosciences plans to launch bezuclastinib

Fairmount Reports Sale of Cogent Biosciences Stock

Cogent Biosciences Submits New Drug Application to FDA

Campbell & CO Increases Holdings in Cogent Biosciences

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

DTIL

COGT

ARKG

LABU

SBIO

Colossal Biosciences has announced that its de-extinct dire wolves, Romulus, Remus, and Khaleesi, are now breeding-aged, with plans to expand the pack later this year. The company aims to create a sustainable population of the world's first de-extinct species through assisted reproduction and natural breeding. Colossal is also pursuing several other de-extinction projects, including the woolly mammoth, thylacine, dodo, and moa, while emphasizing ethical animal welfare and conservation goals. Critics raise concerns about genetic editing and ecological risks, but the company continues to attract global attention for its innovative biotechnology efforts.

ZeroHedge

MBX Biosciences

Precision Biosciences

VG Health

VanEck Biotech ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

SPDR S&P Biotech

ALPS Medical Breakthrough

De-Extinct Dire Wolves Ready To Breed; Bioscience Company Pushes Forward Multiple Projects

Earnings Watch

Cogent Biosciences | 8-K: FY2026 Q1 Revenue: USD 0

Cogent Biosciences (COGT) has released new preclinical data on its KRAS and ErbB2 drug candidates at the AACR 2026 meeting, showcasing selectivity, activity, and safety. The stock is currently priced at $36.81, with a year-to-date return of 5.96% and a total shareholder return of around 7x over the past year. Trading at a price-to-book ratio of 10.8x, Cogent appears expensive compared to the biotech average of 2.3x, but is at a discount to its closer peers. Investors are advised to consider the potential risks and rewards associated with the company.

Simplywall

A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026

BBIO

MLTX

CIGI

Activists also report to the SEC on MoonLake Immunotherapeutics, BridgeBio Pharma, Southwest Airlines, and Cogent Biosciences.

Bridgebio Pharma

Southwest Airlines

MoonLake Immunotherapeutics

Colliers

Southwest Airlines, Colliers International, and more stocks see action from activist investors

Cogent Biosciences (COGT) shares rose 6.1% following the submission of a New Drug Application (NDA) to the FDA for bezuclastinib, aimed at treating imatinib-treated GIST. The application is supported by Phase 3 PEAK data and is under the Real-Time Oncology Review program with Breakthrough Therapy Designation. Despite the positive developments, Cogent remains pre-revenue and faces risks of overvaluation and potential dilution, making regulatory outcomes critical for its investment narrative.

Cogent Biosciences (COGT) Is Up 6.1% After FDA NDA Filing For Bezuclastinib In GIST

Colossal Biosciences, valued at $10.2 billion, is pioneering de-extinction projects, including the woolly mammoth and thylacine, using advanced genome editing techniques. Founded in 2021, the company has raised $615 million and employs 260 scientists. Its innovations are leading to spinoffs addressing plastic pollution, food security, and human fertility. Notably, the BioVault initiative aims to store genetic samples of endangered species, funded by the UAE. Despite skepticism from the scientific community, Colossal's business model anticipates revenue from biodiversity credits and partnerships with governments and tech firms.

Forbes

The $10B Company Behind The Dire Wolf Is Now Bringing Back Mammoths